Cite
HARVARD Citation
Botton, T. et al. (2020). Comment on 'Testing for BRAF fusions in patients with advanced BRAF/NRAS/KIT wild-type melanomas permits to identify patients who could benefit of anti-MEK targeted therapy'. Journal of clinical pathology. 73 (8), pp. 524-525. [Online].